

Nepal

Support for Vaccine: fIPV This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nepal							
2. Vaccine grant number: 14-NPL-08h-Y, 1418-NPL-25d-X, 18-NPL-08p-Y, 19-NPL-25d-X, 20-NPL-25d-X							
3. Date of Decision Letter: 30 September 2019							
4. Date of the Partnership Framework Agreement: 22/08/2014							
5. Programme title: New Vaccine Support (NVS), Fractional IPV (fIPV), Routine							
6. Vaccine type: fIPV							
7. Requested product presentation and formulation of vaccine: Inactivated Polio Vaccine, 1 dose(s) per vial, LIQUID							
8. Programme Duration:¹ 2014-2020							
9. Programme Budget (indicative):² (subject to the terms of the Partnership Framework Agreement, if applicable)							
	2014-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	4,286,749	938,500	-	-	-	-	5,225,249
10. Vaccine introduction grant							
Not applicable							
Approval							
Year	Grant Number		Amount (US\$)				
2014	14-NPL-08h-Y		462,000				
2018	18-NPL-08p-Y		514,078				
Disbursement							
Disbursement date		Amount (US\$)					
25 July, 2014		462,000					
16 January, 2018		514,078					
11. Product switch grant							
Not applicable							
12. Indicative Annual Amounts:³ (subject to the terms of the Partnership Framework Agreement, if applicable)							
Type of supplies to be purchased with Gavi funds	2014-2019	2020					
Number of vaccine doses		314,000	-				
Annual Amounts (US\$)	4,286,749	938,500	-				

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
14. Self-procurement:	Not applicable						
15. Co-financing obligations:	Not applicable						
16. Operational support for campaigns:	Not applicable						
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> 31 March 2020 15 May 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>		Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates						
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020						
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat						
18. Financial clarifications:	Country shall provide the following clarifications to Gavi*: Not applicable * Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.						
19. Other conditions:	Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.						

Signed by,

On behalf of Gavi



Thabani Maphosa

Managing Director, Country Programmes

30 September 2019